| Original language | English |
|---|---|
| Pages (from-to) | 154-156 |
| Number of pages | 3 |
| Journal | Free Radical Biology and Medicine |
| Volume | 189 |
| DOIs | |
| State | Published - Aug 20 2022 |
Bibliographical note
Funding Information:Prof. Mitchell Lai and Prof. Barry Halliwell and co-workers describe clinical research conducted to determine the relationships of levels of the dietary fungus-derived molecule, ergothioneine (ET) that demonstrated considerable antioxidant and cytoprotective characteristics to dementia status of nearly 500 community-based participants [6]. The research groups were divided into 4 classes: persons with no cognitive impairment; persons with mild cognitive impairment; persons with Alzheimer disease (AD) and persons with vascular dementia. All patients involved underwent venipuncture, neuropsychological assessments, and neuroimaging assessments of cerebrovascular disease and brain atrophy. Plasma ET and its metabolite, L-hercynine were determined using high sensitivity liquid chromatography tandem-mass spectrometry. The results supported the hypothesis, i.e., plasma ET levels were lowest in dementia and highest in persons with no cognitive impairment. The authors opine that ET levels could be part of a panel of biomarkers to assess stage of AD and to conceivably ET potentially could provide treatment to slow progression of AD.
ASJC Scopus subject areas
- Biochemistry
- Physiology (medical)